Pediatric Pulmonary Hypoplasia

Pediatric Pulmonary Hypoplasia

No Results

No Results

processing….

Pulmonary hypoplasia (PH) or aplasia is a rare condition that is characterized by incomplete development of lung tissue, which can be unilateral or bilateral. It results in a reduction in the number of lung cells, airways, and alveoli that results in impaired gas exchange. See the image below.

Pulmonary hypoplasia (PH) may be primary or secondary. Primary PH is extremely rare and routinely lethal. The severity of the lesion in secondary PH depends on the timing of the insult in relation to the stage of lung development. This typically occurs prior to or after the pseudoglandular stage at 6-16 weeks of gestation. In pulmonary hypoplasia, the lung consists of incompletely developed lung parenchyma connected to underdeveloped bronchi. Besides disturbances of the bronchopulmonary vasculature, there is a high incidence, (approximately 50-85%) of associated congenital anomalies such as cardiac, gastrointestinal, genitourinary, and skeletal malformations. The diagnosis can result in a spectrum of respiratory complications ranging from transient respiratory distress, chronic respiratory failure, bronchopulmonary dysplasia to neonatal death in very severe cases. Strict diagnostic criteria are not established for pulmonary hypoplasia; various parameters such as lung weight, lung weight to body weight ratio, total lung volume, mean radial alveolar count and lung DNA assessment have been used to classify pulmonary hypoplasia. [1, 2]

For lung development to proceed normally, physical space in the fetal thorax must be adequate, and amniotic fluid must be brought into the lung by fetal breathing movements, leading to distension of the developing lung. Several studies have demonstrated that gestation age at rupture of membranes (15-28 weeks gestation), latency period (duration between rupture of membranes and birth) and the amniotic fluid index (AFI of less than 1 cm or 5 cm) can influence the development of pulmonary hypoplasia. [3]

Maintenance of fetal lung volume plays a major role in normal lung development. Normal transpulmonary pressure of about 2.5mm Hg allows the fetal lung to actively secrete fluid into the lumen. [4] The effect of stretch of the lung parenchyma induces and promotes lung development. Studies in sheep have demonstrated that tracheal ligation and therefore increased lung distension, accelerates lung growth whereas chronic tracheal fluid drainage has the opposite effect. [5] Cohen and colleagues have found that in-utero overexpression of the cystic fibrosis transmembrane conductance regulator (CFTR) increased liquid secretion into the lung, accelerating lung growth in a rat model. [6]

Oligohydramnios is considered to be an independent risk factor for the development of pulmonary hypoplasia. This is likely due to reduced distending forces on the lung. Studies have demonstrated that severe oligohydramnios decreased lung cell size, alters cell shape and may also negatively affect Type I cell differentiation which ultimately induces pulmonary hypoplasia.

It has been postulated that the Rho-ROCK pathway can affect the growth of the lung epithelium. Embryonic mouse models have demonstrated that ROCK protein inhibitor decreases the number of terminal lung buds. There are currently several groups studying the role of the Rho/ROCK pathway which has potential therapeutic implications in the reversal of lung hypoplasia. [7, 8]

Several growth factors such as fibroblast growth factor (FGF), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF), promote cell proliferation and differentiation. Transforming growth factor family proteins like TGFß1 can oppose these effects.

Embryologically, lungs arise from the foregut. Thyroid transcription factor 1 (TTF-1) is thought to be the earliest embryologic marker associated with cells committed to pulmonary development. FGF signaling is thought to be essential in the formation of TTF-1 expressing cells and this is thought to occur even before the pseudoglandular stage of lung development. Sonic hedgehog (SHH) signaling is further responsible for branching morphogenesis and mesenchymal proliferation. Disruption of any of these pathway may result in primary pulmonary hypoplasia. [9, 10, 11, 12]   

FGF7 and FGF10 promote epithelial proliferation and formation of the bronchial tree. Overexpression of FGF10 can also stimulate the formation of cysts in the rat lung. [13] EGF promotes lung branching and Type II alveolar cell proliferation. PDGF plays a crucial role in alveolarization. VEGF promotes angiogenesis and the differentiation of embryonic mesenchymal cells into endothelial cells. Bone morphogenetic protein was thought to oppose lung growth; however recent data suggests that in the presence of mesenchymal cells, BMP4 is a potent inducer of tracheal branching. [14, 15, 16, 17] Aberrant expression of these growth factor proteins in the amniotic fluid during pregnancy have been implicated in abnormal lung development. Interestingly, higher concentrations of VEGF are seen in the amniotic fluid in the second and third trimester and may be a molecular marker for hypoxia which requires further investigation. [15]

The pathogenesis of PH associated with congenital diaphragmatic hernia (CDH) remains unclear. Several mechanisms have been suggested. The nitrofen model of CDH is widely accepted. Nitrofen is a human carcinogen and the retinoid acid signaling pathway is essential for the normal development of the diaphragm. Perturbation of this pathway with compounds such as nitrofen, can induce CDH and PH. Esumi and colleagues demonstrated that that administration of insulin-like growth factor 2 (IGF2) to nitrofen-induced hypoplastic lungs lead to alveolar maturation. [18, 13, 19, 20, 21, 22] Furthermore, recent data suggests that prenatal treatment with retinoic acid results in increased levels of placental IGF2 and promotes both placental and fetal lung growth in nitrofen induced CDH. [23]

Interestingly, erythropoietin (EPO) is a direct target of retinoic acid. A recent study has demonstrated decreased levels of EPO mRNA in the liver and kidney of rats which may explain modifications in the pulmonary vasculature in CDH. [22]

A recent study has also suggested a possible role of interleukin 6 (IL-6) in inducing catch-up growth particularly in nitrofen pre-treated explant fetal rat lungs. [24]

In cases of congenital diaphragmatic hernia (CDH) associated with pulmonary hypoplasia, hypertrophy of the contralateral lung has been demonstrated, with associated pulmonary artery hypertension. The hypoxemia in pulmonary hypoplasia stems from hypoventilation and right-to-left extrapulmonary shunting.

United States

The true incidence of pulmonary hypoplasia is unknown. The reported incidence is between 9 to 11 per 100,00 live birth which is an underestimation, as infants with lesser degrees of hypoplasia likely survive in the neonatal period. [1] Incidence also varies by etiology. Most cases are secondary to congenital anomalies (such as congenital diaphragmatic hernia and cystic adenomatous malformations) or complications related to pregnancy that inhibit lung development. These include, but are not limited to, renal and urinary tract anomalies, amniotic fluid aberrations, diaphragmatic hernia, hydrops fetalis, skeletal and neuromuscular disease and conditions like pleural effusions, chylothorax and intrathoracic masses that cause compression of the fetal thorax. [2]  

The incidence of neonatal pulmonary hypoplasia in mid trimester (18-26 weeks gestation) preterm rupture of membranes ranges from 9-28%, with variability attributed to differing diagnostic criteria for pulmonary hypoplasia.

International

International incidence of pulmonary hypoplasia is not known. In Canada, the estimated incidence of CAM is 1 case per 25,000-35,000 pregnancies. According to the CDH study group the incidence of CDH is 1 in every 2000-4000 births and accounts for 8% of all congenital anomalies. In Europe, the occurrence of CDH ranges from 1.7 to 5.7 cases per 10,000 live births, depending on study population and remains largely unchanged. [8, 25] However, there is no direct correlation between these predisposing lesions to the incidence of pulmonary hypoplasia.

In different studies, mortality rates associated with PH are reported to be as high as 71-95% in the perinatal period. [1, 2]  

The following conditions increase the risk of mortality [25] :

Earlier gestational age at rupture of membranes, particularly at less than 25 weeks of gestation

Severe oligohydramnios (amniotic fluid index < 4) for more than 2 weeks

Earlier delivery (decreased latency period)

Right-sided lesion

Presence of genetic anomalies

To avoid mortality from severe lung hypoplasia in association with CDH or CAM, fetal surgical intervention has been attempted. Most studies report a mortality rate of 25-30% in neonates with CDH and CAM at high volume centers; mortality can be as high as 45% at peripheral care centers. However, in other cystic lung lesions, most are clinically asymptomatic and may not need aggressive management. [26]

Risk factors for a poor outcome include the presence of hydrops fetalis, with a mortality rate as high as 80-90%. Other indicators include the type of CAM and its size. All of these factors reflect the degree of pulmonary compromise with lesions that result in varying degrees of pulmonary hypoplasia.

There is a recent retrospective study from Barcelona that studied 60 cases of pulmonary hypoplasia between 1995 to 2014, that found a mortality rate of 47% in the first 60 days of life and upto 75% in the first day of life. [27]  

No racial predilection has been noted.

No sex predilection has been noted.

Triebwaser JE; Treadwell MC. Prenatal prediction of pulmonary hypoplasia. Seminars in Fetal and Neontal Medicine. 2017. 1-5.

Laudy JAM, Wladimiroff JW. The fetal lung 2: Pulmonary hypoplasia. Ultrasound Obstet Gynecol. 200. 16:482-494.

Winn HN, Chen M, Amon, E, Leet TL, Shumway JB, et al. Neonatal pulmonary hypoplasia and perinatal mortality in patient with midtrimester rupture of amniotic membranes – A critical analysis. American Journal of Obstetrics and Gynecology. 200. 182(6):1638-1644.

Najrana T, Ramos LM, Eid RA, Sanchez-Esteban J. Oligohydramnios Compromises lung cells size and interferes with epithelial-endothelial development. Pediatric Pulmonology. 2017. 52:746-756.

Khan PA, Cloutier M, Piedboeuf B. Tracheal occlusion: a review of obstructing fetal lungs to make them grow and mature. Am J Med Genet Semin Med Genet. 2007. 145c(2):125-138.

Cohen JC, Larson JE. Cystic fibrosis transmembrane conductance regulator (CFTR) dependent cytoskeletal tension during lung organogenesis. Developmental dynamics. 2006. 235:2736-2748.

Moore KA, Polte T, Huang S, Shi B, Alsberg E, Sunday ME, et al. Control of basement membrane remodeling and epithelial branching morphogenesis in embryonic lung by Rho and cytoskeletal tension. Developmental dynamics. 2005. 232:268-281.

Kotecha S, Barbato A, Bush A, et al. Congenital diaphragmatic hernia. Eur Respir J. 2012 Apr. 39(4):820-9. [Medline].

Kugler MC, Joyner AL, Loomis CA, Munger JS. Sonic Hedgehog signaling in the lung. From development to disease. . Am J Respir Cell Mol Biol. 2015. 52(1):

Maeda Y, Dave V, Whitsett J. Transcriptional control of lung morphogenesis. Physiological Reviews. 2007. 87(1):219-244.

Miller LAD, Wert SE, Clark JC, Xu Y, Perl AKT, Whitsett JA. Role of sonic hedgehog in patterning of tracheal-bronchial cartilage and the peripheral lung. Developmental dynamics. 2004. 231:57-71.

DeFelice M, Silberschmidt D, DiLauro R, et al. TTF-1 phosphorylation is required for peripheral lung morphogenesis, perinatal survival, and tissue-specific gene expression. J Biol Chem. 2003. 278(37):355744-83. [Medline].

Gonzaga S, Henriques-Coelho T, Davey M, et al. Cystic adenomatoid malformations are induced by localized FGF10 overexpression in fetal rat lung. Am J Respir Cell Mol Biol. 2008. 39(3):346-55.

Logan JW, Rice HE, Goldberg RN, Cotten CM. Congenital diaphragmatic hernia: a systematic review and summary of best-evidence practice strategies. J Perinatol. 2007 Sep. 27(9):535-49. [Medline].

Bedaiwy MA, Burlingame JM, Hussein M, Flyckt R, Assad R, Falcone T. Assessment of vascular endothelial growth factor, basic fibroblast growth factor and transforming growth factor levels in amniotic fluid. J Reprod Med. 2012. 57:405-410.

Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet. 2012 Feb 11. 379(9815):537-46. [Medline].

Warburton D, Bellusci S, De Langhe S, et al. Molecular mechanisms of early lung specification and branching morphogenesis. Pediatr Res. 2005. 57:26R-37R.

Esumi G, Masumoto K, Teshiba R, et al. Effect of insulin-like growth factors on lung development in a nitrofen-induced CDH rat model. Pediatr Surg Int. 2011 Feb. 27(2):187-92. [Medline].

Sbragia L, Nassr AC, Gonçalves FL, et al. VEGF receptor expression decreases during lung development in congenital diaphragmatic hernia induced by nitrofen. Braz J Med Biol Res. 2014 Feb. 47(2):171-8. [Medline].

Jay PY, Bielinska M, Erlich JM, et al. Impaired mesenchymal cell function in Gata4 mutant mice leads to diaphragmatic hernias and primary lung defects. Dev Biol. 2007 Jan 15. 301(2):602-14. [Medline]. [Full Text].

Kamath-Rayne BD, Saal H, Lang S, Habli M. Recurrent severe oligohydramnios and fetal pulmonary hypoplasia associated with ErbB4 mutation. Obstet Gynecol. 2013 Feb. 121(2 Pt 2 Suppl 1):499-501. [Medline].

Gonzalez-Reyes S, Martinez L, Martinez-Calonge W, Fernandez-Dumont V, Tovar JA. Effects of antioxidant vitamins on molecular regulators involved in lung hypoplasia induced by nitrofen. J Pediatr Surg. 2006 Aug. 41(8):1446-52. [Medline].

Kutasy B, Friemacher F, Duess JW, Puri P. Prenatal administration of retinoic acid increases the trophoblastic insulin-like-growth factor 2 protein expression in the nitrofen model of congenital diaphragmatic hernia. Pediatric Surg Int. 2014. 30(2):137-142.

Takayasu H, Hagiwara K, Masumoto K. Suppressed erythrompoeitin expression in a nitrofen-induced congenital diaphragmatic hernia. Pediatric Pulmonology. 2017. 52:606-615.

Burgos CM, Frencher B. Addressing the hidden mortality in CDH: A population-based study. J Pediatr Surg. 2017. 52(4):522-525.

Bush A, Hogg J, Chitty LS. Cystic lung lesions – prenatal diagnosis and management. Prenat Diagn. 2008 Jul. 28(7):604-11. [Medline].

Delgado-Pena YP, Torrent-Vernetta A, Socoto G, Messa IDM, Rovira-Amigo S, Gartner S, et al. Pulmonary hypoplasia: An analysis of cases over a 20 year period. An Pediatr. 2016. 85(2):70-6.

Shinohara G, Morita K, Yamashiro M, Hashimoto K. Scimitar syndrome in an infant with right lung hypoplasia, ventricular septa defect, and severe pulmonary hypertension. General Thorac Cardivasc Surg. 2010. 58(10):524-527.

Deli T, Kovacs T. Pena Shokei syndrome type1 – combination of polyhydramnios and pulmonary hypoplasia in fetal akinesia. Orv Hetil. 2010. 151(24):990-993.

Russell BC, Whitecar P, Nitsche JF. Isolated unilateral pulmonary agenesis and other fetal thoracic anomalies. Obstet Gynecol Surv. 2014. 69(6):335-345.

Baguma-Nibasheka M, Kablar B. Pulmonary hypoplasia in the connective tissue growth factor (Ctgf) null mouse. Dev Dyn. 2008 Feb. 237(2):485-93. [Medline].

Vergani P. Prenatal diagnosis of pulmonary hypoplasia. Curr Opin Obstet Gynecol. 2012 Mar. 24(2):89-94. [Medline].

Vergani P, Andreani M, Greco M, Farina G, Fedeli T, Cuttin S. Two or three-dimensional ultrasonography: which is the best predictor of pulmonary hypoplasia?. Prenatal Diagnosis. 2010. 30:834-838.

Gerards FA, Twisk JW, Fetter WP, Wijnaendts LC, van Vugt JM. Two- or three-dimensional ultrasonography to predict pulmonary hypoplasia in pregnancies complicated by preterm premature rupture of the membranes. Prenatal Diagnosis. 2007. 27(3):216-221.

Barros CA, Rezende GDC, Junior EA, Tonni G, Pereira AK. Prediction of lethal pulmonary hypoplasia by means fetal lung volumes in skeletal dysplasias: a three-dimensional ultrasound assessment. The journal of Maternal-Fetal & Neonatal Medicine. 2016. 29(11):1725-1730.

Tsukimori K, Masumoto K, Morokuma S, et al. The lung-to-thorax transverse area ratio at term and near term correlates with survival in isolated congenital diaphragmatic hernia. J Ultrasound Med. 2008 May. 27(5):707-13. [Medline].

Hofmann AD, Friedmacher F, Takahashi T, Gosemann JH, Puri P. Increased pulmonary vascular expression of receptor of advanced glycation end products (RAGE) in experimental congenital diaphragmatic hernia. Journal of Pediatric Surgery. 2015. 50:746-749.

Gerards FA, Twisk JW, Vugt Van. Doppler velocimetry o the ductus arteriosus in normal fetuses and fetuses suspected for pulmonary hypoplasia. Fetal Diagn Ther. 2009. 26:143-147.

Lin AE, Pober BR, Adatia I. Congenital diaphragmatic hernia and associated cardiovascular malformations: type, frequency, and impact on management. Am J Med Genet C Semin Med Genet. 2007 May 15. 145C(2):201-16. [Medline].

Obenauer S, Maestre LA. Fetal MRI of lung hypoplasia: imaging findings. Clin Imaging. 2008 Jan-Feb. 32(1):48-50. [Medline].

Taylor GA, Atalabi OM, Estroff JA. Imaging of congenital diaphragmatic hernias. Pediatr Radiol. 2009 Jan. 39(1):1-16. [Medline].

Matsushita M, Ishii K, Tamura M, et al. Perinatal magnetic resonance fetal lung volumetry and fetal lung-to-liver signal intensity ratio for predicting short outcome in isolated congenital diaphragmatic hernia and cystic adenomatoid malformation of the lung. J Obstet Gynaecol Res. 2008 Apr. 34(2):162-7. [Medline].

Okuyama H, Kubota A, Kawahara H, Oue T, Kitayama Y, Yagi M. Correlation between lung scintigraphy and long-term outcome in survivors of congenital diaphragmatic hernia. Pediatr Pulmonol. 2006 Sep. 41(9):882-6. [Medline].

Pantich HB, Weiner, DJ, Feng R, Perez MR, Healy F, et al. Lung function over the first 3 years of life in children with congenital diaphragmatic hernia. Pediatric Pulmonology. 2014. 49(1):60=66.

Koumbourlis AC, Wung JT, Stolar CJ. Lung function in infants after repair of congenital diaphragmatic hernia. J Pediatr Surg. 2006 Oct. 41(10):1716-21. [Medline].

De Paepe ME, Shapiro S, Hansen K, Gündogan F. Postmortem lung volume/body weight standards for term and preterm infants. Pediatr Pulmonol. 2014 Jan. 49(1):60-6. [Medline].

Reianec V, Krizko MJ, Papcun P, Svitekova K, Cizmar B, Holly I, et al. Amniopathcy – possibility of successful treatment of spontaneous previable rupture of membranes in the second trimester of pregnancy by transabdominal intramaniotic application of platelets and cryoprecipitate. Neruo Endocrinol Lett. 2011. 34(4):449-452.

Kozinszky Z, SikovanyeczJ, Pasztor. Severe midtrimester oligohydramnios: treatments strategies. Curr Opin Obstet Gynecol. 2014. 26(2):67-76.

Garcia A, Stolar CJ. Congenital diaphragmatic hernia and protective ventilation strategies in pediatric surgery. Surg Clin North Am. 2012 Jun. 92(3):659-68, ix. [Medline].

Weidner M, Hagelstein C, Debus A, Walleyo A, Weiss C, Schoenber SO, et al. MRI-Based Ratio of fetal lung volume to fetal body volume as a new prognostic marker in congenital diaphragmatic hernia. American Journal of Roetgenology. 2014. 202(6):1330-1336.

Prabhu S, Mattke AC, Anderson B, McBride C, Cooke L, Karl T, et al. Repair of congental diaphragmatic hernias during extracorporeal life support: experience with six neonates. ANZ Journal of Surgery. 2016. 56(9):711-716.

Golden J, Jones N, Zagory J, Castle S, Bliss D. Outcomes of congenital diaphragmatic hernia repair on extracorporeal life support. Pediatric Surgery International. 2017. 33(2):125-131.

Keszler M. Guidelines for Rational and Cost-Effective Use of iNO Therapy in Term and Preterm Infants. J Clin Neonatol. 2012 Apr. 1(2):59-63. [Medline]. [Full Text].

Tiryaki S, Ozcan C, Erdener A. Initial oxygenation response to inhaled nitric oxide predicts improved outcomes in congenital diaphragmatic hernia. Drugs D R. 2014. 14(4):215-219.

Cogo PE, Simonato M, Danhaive O, et al. Impaired surfactant protein B synthesis in infants with congenital diaphragmatic hernia. Eur Respir J. 2013 Mar. 41(3):677-82. [Medline].

Kaushal A, McDonnell CG, Davies MW. Partial liquid ventilation for the prevention of mortality and morbidity in paediatric acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev. 2013 Feb 28. 2:CD003845. [Medline].

Morikawa N, Kuroda T, Honna T, et al. The impact of strict infection control on survival rate of prenatally diagnosed isolated congenital diaphragmatic hernia. Pediatr Surg Int. 2008 Oct. 24(10):1105-9. [Medline].

Khalek N, Johnson MP. Management of prenatally diagnosed lung lesions. Semin Pediatr Surg. 2013 Feb. 22(1):24-9. [Medline].

Fitzgerald DA. Congenital cyst adenomatoid malformations: resect some and observe all?. Paediatr Respir Rev. 2007 Mar. 8(1):67-76. [Medline].

Nicolai T. Management of the upper airway and congenital cystic lung diseases in neonates. Semin Fetal Neonatal Med. 2009 Feb. 14(1):56-60. [Medline].

Wilson RD. In utero therapy for fetal thoracic abnormalities. Prenat Diagn. 2008 Jul. 28(7):619-25. [Medline].

Wu CS, Chen CM, Chou HC. Pulmonary Hypoplasia Induced oligohydramnios: findings from animal models and a populations based study. Pediatrics and Neonatology. 2017. 58(1):3-7.

Morris RK, Malin GL, Quinlan-Jones E, et al. Percutaneous vesicoamniotic shunting versus conservative management for fetal lower urinary tract obstruction (PLUTO): a randomised trial. Lancet. 2013 Nov 2. 382(9903):1496-506. [Medline]. [Full Text].

Gucciardo L, Deprest J, Done’ E, et al. Prediction of outcome in isolated congenital diaphragmatic hernia and its consequences for fetal therapy. Best Pract Res Clin Obstet Gynaecol. 2008 Feb. 22(1):123-38. [Medline].

Cundy TP, Gardener GJ, Andersen CC, Kirby CP, McBride CA, Teague WJ. Fetoscopic endoluminal tracheal occlusion (FETO) for congenital diaphragmatic hernia in Australia and New Zealand: are we willing, able, both or neither?. J Paediatr Child Health. 2014 Mar. 50(3):226-33. [Medline].

Braga AFA, Braga FSS, Nscimento SP, Varri B, Peralta F, Junior JB, et al. Fetoscopic tracheal occlusion for severe congenital diaphragmatic hernia: a retrospective study. Rev Bras Anestesiol. 2016.

Belfort M, Olutoye O, Cass Darrell, Cassady C, Meholin-Ray A, Shamshirsaz A, et al. Feasibility and outcomes of fetoscopic tracheal occlusion for severe left diaphragmatic hernia. Obstetrics and Gynecology. 2017. 129(1):20-29.

Coasterus S, Zahn K, van de Ven K, Vlot J, Wessel L, Wijnen R. Thoracoscopic versus open repair of CDH in cardiovascular stable neonates. Surd Endosc. 2016. 30(7):2818-24.

Badillo A, Gingalewski C. Congenital diaphragmatic hernia: treatment and outcomes. Semin Perinatol. 2014 Mar. 38(2):92-6. [Medline].

Partridge EA, Peranteau WH, Rintoul NE, Herkert LM, Flake AW, Adzick NS, et al. Timing of repair of congenital diaphragmatic hernia in patients supported by ECMO. J Pediatr Surg. 2015. 50(2):260-2.

Hedrick HL. Management of prenatally diagnosed congenital diaphragmatic hernia. Semin Pediatr Surg. 2013 Feb. 22(1):37-43. [Medline].

Danzer E, Zarnow D, Gerdes M, et al. Abnormal brain development and maturation on magnetic resonance imaging in survivors of severe congenital diaphragmatic hernia. J Pediatr Surg. 2012 Mar. 47(3):453-61. [Medline].

Chemin A, Bonnet D, Le Bourgeois M, Levy M, Delacourt C. Respiratory outcome in children with scimitar syndrome. J Pediatr. 2013 Feb. 162(2):275-9.e1. [Medline].

Partridge EA, Peranteau WH, Herkert LM, Rendon N, Smith H, Rontoul NE, et al. Right-versus left-sided congenital diaphragmatic hernia : a comparative outcomes analysis. Pediatr Surg. 2016. 51(6):900-2.

Collin M, Trinder S, Minutillo C, Rao S, Dickinson J, Samnakay N. A modern era comparison of right versus left sided congenital diaphragmatic hernia outcomes. J Pediatr Surg. 2016. 51(9):1409-13.

Transcription Factors

Growth Factors

Thyroid transcription factor-1 (TTF-1) [12]

Vascular endothelial growth factor receptors (VEGFR1 and VEGFR2) [15]

GATA-4 [20]

Insulinlike growth factors (IGF-1 and IGF-2) and their receptors (IGF-1R and IGF-2R) [18]

FOG-2 [23]

Epidermal growth factors and its receptor family (eg, ErbB receptors) [21]

Hepatocyte nuclear factor (HNF3ß10)

Mitogen-activated protein kinases

 

Connective tissue growth factor [31]

Small Fetal Thoracic Volume

Prolonged Oligohydramnios

Decreased Fetal Breathing Movements

Congenital Heart Diseases With Poor Pulmonary Blood Flow

CDH

Fetal renal agenesis

Central nervous system (CNS) lesions

Tetralogy of Fallot

Cystic adenomatoid malformation (CAM)

Urinary tract obstruction

Lesions of the spinal cord, brain stem, and phrenic nerve

Hypoplastic right heart

Pulmonary sequestration

Bilateral renal dysplasia

Neuromuscular diseases (eg, myotonic dystrophy, spinal muscular atrophy)

Pulmonary artery hypoplasia

Pleural effusions with fetal hydrops, hydrothorax

Bilateral cystic kidneys

Arthrogryposis multiplex congenital secondary to fetal akinesia

Scimitar syndrome causing a unilateral right-sided pulmonary hypoplasia

Thoracic neuroblastomas

Prolonged rupture of membranes (PROM)

Maternal depressant drugs

Trisomies 18 and 21

Malformations of the thorax (eg, asphyxiating thoracic dystrophy)

Premature PROM

 

 

Diaphragmatic anomalies (eg, abdominal wall defects, eventration of the diaphragm)

Potter syndrome

 

 

Musculoskeletal disorders (eg, achondroplasia, thanatophoric dysplasia, osteogenesis imperfecta)

 

 

 

Abdominal masses causing compression

 

 

 

Terry W Chin, MD, PhD Associate Clinical Professor, Department of Pediatrics, University of California, Irvine, School of Medicine; Associate Director, Cystic Fibrosis Center, Attending Staff Physician, Department of Pediatric Pulmonology, Allergy, and Immunology, Memorial Miller Children’s Hospital

Terry W Chin, MD, PhD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Association of Immunologists, American College of Allergy, Asthma and Immunology, American College of Chest Physicians, American Federation for Clinical Research, American Thoracic Society, California Society of Allergy, Asthma and Immunology, California Thoracic Society, Clinical Immunology Society, Los Angeles Pediatric Society, Western Society for Pediatric Research

Disclosure: Nothing to disclose.

Nandini Kataria, MD Fellow in Pediatric Pulmonology, Miller Children’s and Women’s Hospital Long Beach, University of California, Irvine, School of Medicine

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Girish D Sharma, MD, FCCP, FAAP Professor of Pediatrics, Rush Medical College; Director, Section of Pediatric Pulmonology and Rush Cystic Fibrosis Center, Rush Children’s Hospital, Rush University Medical Center

Girish D Sharma, MD, FCCP, FAAP is a member of the following medical societies: American Academy of Pediatrics, American College of Chest Physicians, American Thoracic Society, Royal College of Physicians of Ireland

Disclosure: Nothing to disclose.

Susanna A McColley, MD Professor of Pediatrics, Northwestern University, The Feinberg School of Medicine; Director of Cystic Fibrosis Center, Head, Division of Pulmonary Medicine, Children’s Memorial Medical Center of Chicago

Susanna A McColley, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Chest Physicians, American Sleep Disorders Association, American Thoracic Society

Disclosure: Received honoraria from Genentech for speaking and teaching; Received honoraria from Genentech for consulting; Partner received consulting fee from Boston Scientific for consulting; Received honoraria from Gilead for speaking and teaching; Received consulting fee from Caremark for consulting; Received honoraria from Vertex Pharmaceuticals for speaking and teaching.

Khanh Van Lai, MD Fellow in Pediatric Pulmonology, Miller Children’s Hospital, University of California, Irvine, School of Medicine

Khanh Van Lai, MD is a member of the following medical societies: American Thoracic Society

Disclosure: Nothing to disclose.

Bich-Trang Hoa, MD Fellow in Pediatric Pulmonology, Miller Children’s Hospital, University of California, Irvine, School of Medicine

Disclosure: Nothing to disclose.

The current authors would like to acknowledge the contributions of the following to this article:

Heidi Connolly, MD Associate Professor of Pediatrics and Psychiatry, University of Rochester School of Medicine and Dentistry; Director, Pediatric Sleep Medicine Services, Strong Sleep Disorders Center;

Girija Natarajan, MD, Assistant Professor, Division of Neonatology, Children’s Hospital of Michigan, Wayne State University School of Medicine; and

Ibrahim Abdulhamid, MD, Associate Professor of Pediatrics, Wayne State University School of Medicine; Director of Pediatric Pulmonary Medicine, Clinical Director of Pediatric Sleep Laboratory, Children’s Hospital of Michigan

Disclosure: Nothing to disclose.

Pediatric Pulmonary Hypoplasia

Research & References of Pediatric Pulmonary Hypoplasia|A&C Accounting And Tax Services
Source